期刊
JOURNAL OF PAIN RESEARCH
卷 7, 期 -, 页码 531-545出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/JPR.S65923
关键词
endothelin-1; acute pain; chronic pain; endothelin receptor antagonists
资金
- National Institutes of Health [R01 DA023593, NS26363, R25 GM066526, R25 GM076277]
- Alfred P Sloan Foundation
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM066526, R25GM076277] Funding Source: NIH RePORTER
Many people worldwide suffer from pain and a portion of these sufferers are diagnosed with a chronic pain condition. The management of chronic pain continues to be a challenge, and despite taking prescribed medication for pain, patients continue to have pain of moderate severity. Current pain therapies are often inadequate, with side effects that limit medication adherence. There is a need to identify novel therapeutic targets for the management of chronic pain. One potential candidate for the treatment of chronic pain is therapies aimed at modulating the vasoactive peptide endothelin-1. In addition to vasoactive properties, endothelin-1 has been implicated in pain transmission in both humans and animal models of nociception. Endothelin-1 directly activates nociceptors and potentiates the effect of other algogens, including capsaicin, formalin, and arachidonic acid. In addition, endothelin-1 has been shown to be involved in inflammatory pain, cancer pain, neuropathic pain, diabetic neuropathy, and pain associated with sickle cell disease. Therefore, endothelin-1 may prove a novel therapeutic target for the relief of many types of chronic pain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据